Before ordering a genomic test for your lung cancer patient, remember that not all genomic tests are alike. FoundationOne®, offered by Foundation Medicine, is a comprehensive genomic profiling test that examines the entire coding region of 315 cancer-related genes. The assay can accurately detect all 4 classes of genomic alterations associated with lung cancer with >99% specificity.1 This gives you a comprehensive assessment to help you determine a tailored treatment from one test, from one tissue sample, with results delivered within 2 weeks.
Hotspot testing and single-gene tests often miss critical genomic information and require separate tissue samples for each test.
Not only can comprehensive genomic profiling identify therapeutic targets missed by hotspot and single gene testing, but it can also provide more clinically actionable data relevant to lung cancer. In one study, hotspot testing alone was associated with a 17% false negative rate of drug-sensitive EGFR mutations.2
Comprehensive genomic profiling identified clinically actionable alterations in 65% of lung adenocarcinoma tumors previously deemed non-actionable by hotspot testing.3 More than 30% of patients may have clinically actionable alterations not previously discovered with hotspot testing.4
For those patients whose tissue is scarce or rebiospy is not an option, we offer FoundationACT™, a blood-based circulating tumor DNA assay, designed to interrogate the 62 most druggable cancer-related genes.
Don’t delay. Order FoundationOne or FoundationACT for your lung cancer patient.
1. Frampton et al. Development and Validation of a Clinical Cancer Genomic Profiling Test Based on Massively Parallel DNA Sequencing. Nature Biotechnology. 2013; 31:1023-1031.
2. Schrock et al. Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing. Clinical Cancer Research. 2016;13:3281-3285.
3. Drilon et al. Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Clinical Cancer Research. 2015;21(16):3631-3639.
4. Lim et al. Genomic Profiling of Lung Adenocarcinoma Patients Reveals Therapeutic Targets and Confers Clinical Benefit When Standard Molecular Testing is Negative. Oncotarget. 2016;7(17):24172-24178.